DAY 2

 

Atherosclerosis: the intricate dance of immunometabolic factors

Unrecognized drivers of cardiometabolic disease (NASH, microbiota…

 

SADAF FAROOQI

PROFESSOR OF METABOLISM & MEDICINE 

@ UNIVERSITY OF CAMBRIDGE

Genetics of Monogenic Obesities:
Toward New Therapies

Sadaf Farooqi qualified with Honours in Medicine from the University of Birmingham, being awarded the gold medal. After hospital posts in Birmingham and Oxford she moved to Cambridge to undertake a PhD. She identified the first single gene defect to cause human obesity in patients with a mutation in the leptin gene, published in Nature in 1997 and described their dramatic response to leptin therapy (NEJM 1999; SCIENCE 2007). As a Wellcome Trust Senior Clinical Fellow at the Institute of Metabolic Science in Cambridge, Professor Farooqi co-ordinates a programme of research into the genetic, molecular and physiological basis of human obesity. She has been invited to speak at numerous international meetings and has been the recipient of a number of awards in recognition of her contribution to Endocrinology including the Andre Mayer Award 2006 (International Association for the Study of Obesity), the RD Lawrence Award 2007 (Diabetes UK), the Society for Endocrinology Medal 2012 and the European Society for Endocrinology Prize 2012.

JOSÉ TIMSIT

PROFESSOR OF DIABETES @ COCHIN-PORT-ROYAL HOSPITAL

Monogenic Diabetes: Back to Bedside

José Timsit is a diabetologist at Port-Royal/Cochin Hospital (AP-HP) in Paris, and a professor of internal medicine at Paris Descartes University. He his involved in clinical care, teaching and clinical research. His main areas of interest are the care of women with diabetes during pregnancy and the clinical aspects of monogenic diabetes.

LEX VAN DER PLOEG

CHIEF SCIENTIFIC OFFICER @ RHYTHM PHARMACEUTICALS

Targeted Drugs in Rare Diseases: the MC4 Pathway

Lex H.T. Van der Ploeg is Managing Director for VDP, LLC, an independent consulting agency focused on guiding Research and Development for the Biotechnology and Pharmaceutical Industries and private investors. Lex is CSO for Rhythm pharmaceuticals and functions as a member of the board of Directors for Retrotope Inc., and as an advisor to DeuteRx, LLC. Lex’s expertise includes development of Diagnostics and Therapeutics including Cancer, Neurodegenerative disorders, Metabolic disorders and Infectious diseases. Lex has made notable contributions to a diverse range of basic research fields and the medical sciences. Dr. Van der Ploeg received his M.S. degree (Summa Cum Laude) in Biochemistry in 1980 from the University of Amsterdam and his Ph.D. in Biochemistry/ Enzymology/Genetics in 1984 from the University of Amsterdam/Netherlands Cancer Research Center. Following receipt of his Ph.D. Dr Van der Ploeg joined the faculty of the Dept of Genetics and Development of Columbia University, as an assistant Professor and received tenure at Columbia University in 1987. Dr Van der Ploeg held an adjunct faculty position at the Dept of Genetics and Development of Columbia University from 1992 through 2009. Dr. Van der Ploeg received numerous awards and grants for his research and has broadly published on his research in peer reviewed journals. He is an inventor on over 50 patents and patent applications.

FLORIAN ABEL

ALEXION PHARMACEUTICALS

Lysosomal Acid Lipase Deficiency:
Challenges in Diagnosing a Heterogeneous Cardiometabolic & Hepatic Disease

 
 
 
Logo ICAN Series 2019 inset blanc.png
Connect to ICAN

Subscribe for ICAN Series updates

@2018 by ICAN. Proudly created with wix.com